前列地尔联合贝那普利对糖尿病肾病患者尿蛋白、白蛋白水平的影响

目的 探讨前列地尔联合贝那普利对糖尿病肾病患者尿蛋白、白蛋白水平的影响.方法 采用整群随机抽样的方法选取我院2015年1月至2016年7月收治的80例糖尿病肾病患者,依据随机数表法将其分为前列地尔联合贝那普利治疗组(联合治疗组,n=40)和单纯贝那普利治疗组(单独治疗组,n=40),对两组患者的24h尿蛋白含量、24 h尿微白蛋白排泄率、临床疗效、不良反应发生情况进行统计分析.结果 治疗后联合治疗组患者的24 h尿蛋白含量(1.30±0.11)g/d]、24 h尿微白蛋白排泄率(492.5±30.6)mg/d]均显著低于单独治疗组(1.87±0.30)g/d、(612.2±38.7)mg/d],差异有统计学意义(P<0.05),联合治疗组的总有效率95.0％(38/40)]显著高于单独治疗组77.5％(31/40)],差异有统计学意义(P<0.05);两组患者的不良反应发生率15.0％(6/40)、12.5％(5/40)]差异无统计学意义(P>0.05).结论 前列地尔联合贝那普利较单纯贝那普利更能有效降低糖尿病肾病患者的尿蛋白、白蛋白水平,且不会提高患者的不良反应发生率.

Effects of alprostadil combined with benazepril on levels of urinary protein and albumin in patients with diabetic nephropathy

Objective To investigate the effects of alprostadil combined with benazepril on the levels of uri-nary protein and albumin in the patients with diabetic nephropathy. Methods Eighty patients with diabetic nephropathy in the Affiliated Hospital of Hainan Medical College from January 2015 to July 2016 who were selected by cluster ran-dom sampling method were divided into two groups:alprostadil combined with benazepril (combined treatment group, n=40) and benazepril alone (single treatment group, n=40). The 24 h urinary protein contents, 24 h urinary micro albumin ex-cretion rates, clinical efficacy and adverse reactions of the two groups were statistically analyzed. Results The 24 h uri-nary protein contents, 24 h urine micro albumin excretion rates in the combined treatment group were (1.30±0.11) g/d and (492.5 ± 30.6) mg/d, which were significantly lower than (1.87 ± 0.30) g/d and (612.2 ± 38.7) mg/d in the single treatment group (P<0.05). The total treatment efficiency in the combined treatment group was 95.0％(38/40), which was significant-ly higher than 77.5％(31/40) in the single treatment group (P<0.05). The incidence of adverse reactions was 15.0％(6/40) in the combined group and 12.5％ (5/40) in the single treatment group, showing no significant differences (P>0.05). Conclusion Alprostadil combined with benazepril is more effective in reducing the levels of proteinuria and serum albu-min than benazepril alone, which will not increase incidence of adverse reactions in patients with diabetic nephropathy.